甘李药业 (603087)

Gan and Lee Pharmaceuticals

ASH

Tags

SSE Corporate Governance IndexWeight Loss DrugsInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareGene ConceptPrivate Enterprises 100 IndexBiological ProductsHigh-Performing StocksMargin Trading and Securities LendingNon-Cyclical Stocks医药生物

K-Line Chart

No K-line data available

Company NameGan & Lee Pharmaceuticals Co., Ltd.
Listing Date2020-06-29
Issue Price63.32RMB
Registered Capital59730.496910k RMB
Legal RepresentativeChen Wei
Registered AddressNo. 8 Nanfeng West 1st Road, Huoxian Town, Tongzhou District, Beijing
IndustryBiological Products
Main BusinessThe company is primarily engaged in the R&D, production, and sales of recombinant insulin analog active pharmaceutical ingredients (APIs) and injections.
Company ProfileGan & Lee Pharmaceuticals Co., Ltd. was founded in 1998 and is a high-tech biopharmaceutical enterprise integrating scientific research, development, production, and sales. Its headquarters is located in the South Zone of Beijing Tongzhou Economic Development Area, belonging to the Zhongguancun National Innovation Demonstration Zone. The company has an industrial park of approximately 200,000 square meters and employs nearly 2,500 staff. As the first company in China to master the industrialized production technology of recombinant insulin analogs, Gan & Lee holds a leading position in the Chinese diabetes market for its biosynthetic human insulin and its analogs in production and R&D. It has established close cooperation with renowned global enterprises such as Sandoz. Today, as a global enterprise dedicated to human health, Gan & Lee adheres to a corporate culture of science and excellence, committed to providing high-quality products and services for diabetes patients worldwide.

Stock Details

1. Key Indicators

  • Total Shares(W): 59752.53
  • Circulating A-Shares(W): 55785.86
  • Earnings Per Share(RMB): 1.3800
  • Net Assets Per Share(RMB): 18.8819
  • Operating Revenue(W RMB): 304703.91
  • Total Profit(W RMB): 92571.00
  • **Net Profit Attributable to Parent(W RMB) **: 81833.96
  • Net Profit Growth Rate(%): 61.32
  • Weighted Return on Equity(%): 7.2100
  • Operating Cash Flow Per Share(RMB): 0.8070
  • Undistributed Profit Per Share(RMB): 11.6813
  • Capital Reserve Per Share(RMB): 5.8939

2. Main Business

The main business covers:

  • Research, production, and sales of recombinant insulin analog APIs and injections.

3. Company Basic Information

  • Company Name: Gan & Lee Pharmaceuticals Co., Ltd.
  • Listing Date: 2020-06-29
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 8 Nanfeng West 1st Road, Huoxian Town, Tongzhou District, Beijing
  • Website: https://www.ganlee.com/
  • Company Profile: Gan & Lee Pharmaceuticals Co., Ltd. was formerly known as Beijing Gan & Lee Biotechnologies Co., Ltd. Gan & Lee Biotechnologies was established on June 17, 1998, approved by the Tongzhou Branch of the Beijing Administration for Industry and Commerce, with shareholders being Gan Zhongru, Gan Yiru, and Gan Xiru. On April 13, 2005, Gan & Lee Biotechnologies underwent a change.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Beijing Xute Hongda Technology Co., Ltd. Corporate Entity 3207.37 5.75
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 800.42 1.43
3 CSI 500 Exchange Traded Fund Fund 525.96 0.94
4 China Merchants CSI Bio-medicine Index Fund (LOF) Class A Fund 490.43 0.88
5 Yinhua CSI Innovative Pharma Industry ETF Fund 357.73 0.64
6 Southern Alpha Mixed Securities Investment Fund Class A Fund 264.69 0.47
7 China Life Insurance Company Limited - Traditional - General Insurance Products - 005L-CT001 Shanghai Corporate Entity 210.73 0.38
8 Changsheng High-end Equipment Manufacturing Flexible Allocation Mixed Securities Investment Fund Class A Fund 192.91 0.35
9 Tianhong CSI Bio-medicine Exchange Traded Fund Fund 172.28 0.31
10 Southern High Growth Mixed Securities Investment Fund Fund 128.21 0.23

5. Concept Sectors

  • Gene Concept
  • Innovative Drugs
  • Weight-loss Drugs
  • Margin Trading & Securities Lending
  • Blue-chip Stocks
  • Non-cyclical Stocks
  • SSE Governance
  • Private Enterprise 100

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information